To the editor,

There have been more than 40,000 reported cases of coronavirus disease (COVID-19) in Brazil until May 8, 2020. Recurrent testing among health care professionals is the key step to be undertaken by hospitals, as completely asymptomatic infection might occur among these professionals. Hospital das Clinicas is the main hospital dedicated to COVID-19 response in the city of Sao Paulo, with 224 intensive care unit beds.

We have set up a PCR testing program to detect COVID-19 among symptomatic health care professionals in the early phase of the epidemic. However, an antibody-based screening program was difficult to establish because of the lack of available antibody tests in Brazil. Recently, we received a donation of Wondfo One Step COVID-19 rapid test kits (Guangzhou, China) from a Brazilian company. The test is generally performed on capillary blood samples, but it can also be performed on peripheral blood, plasma, and serum.

We collected 47 paired samples (capillary and serum) from health care workers within 15 days of their confirmed diagnosis of COVID-19 by PCR to validate the test. The results were compared with those of the Euroimmun IgG EIA test (Luebeck, Germany).

The results of the test have been summarized in [Table 1](#t01){ref-type="table"}. The rapid test showed a low sensitivity when performed with capillary blood (55%); however, when tested on serum samples it exhibited a similar sensitivity to that of the Euroimmun IgG EIA assay (96%).

Table 1Comparison of the Wondfo One Step COVID‐19 test (capillary and serum samples) and Euroimmun IgG EIA test results.Wondfo One Step COVID-19 testEuroimmun IgG testCapillary bloodPositiveNegative    Positive26    Negative192Serum    Positive45    Negative2

Recently, the government of Brazil has purchased a considerable number of Wondfo rapid test kits. Our results indicate that this test should not be performed using capillary blood but rather be performed with plasma or serum.
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